Shots:

• The P-III (CONTACT-03) trial evaluates the efficacy & safety of cabozantinib + atezolizumab vs cabozantinib alone in a ratio (1:1) in 523 patients with LA or metastatic clear cell or non-clear cell RCC who progressed during or following treatment with an ICI. The trial is sponsored by Roche & co-funded by Exelixis
• The 1EPs of the trial are OS & PFS as assessed by IRR. The 2EPs include PFS, ORR & DoR as assessed by investigators
• Cabometyx is approved in the US for advanced RCC, HCC, for patients with advanced RCC as a 1L treatment in combination with nivolumab & for LA or metastatic differentiated thyroid cancer. The therapy is also approved in the EU & and other and regions globally

Ref: Businesswire | Image: Pharma Advancement